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Abstract
Expanding research has shown, exposure to traumatic events increases the likelihood of
developing a medical illness, mental disorder, substance use disorder, or comorbid conditions
(Halter, 2014; Center for Behavioral Health Statistics and Quality, 2016; Child Welfare
Information Gateway, 2013; National Institute of Mental Health, 2017). The Federal Drug
Administration has approved medications for the treatment of alcohol use disorder, opioid use
disorder and post-traumatic stress disorder (PTSD) symptoms; a medication for the treatment of
methamphetamine use disorder, has yet to emerge (Perese, 2012; Stahl, 2013). The focus of
research and this paper is to review current evidence on pharmacotherapy alone or in
combination with psychotherapy, in the treatment of co-occurring stimulant use disorder
methamphetamine-type and PTSD. Conducive to identifying all relevant studies, multiple
bibliographic databases were used to complete a comprehensive search of evidence, including:
MEDLINE, Pubmed, CINAHL, and PsycINFO. Searched keyword phrases included: stimulant
use disorder methamphetamine-type, PTSD, cooccurring disorder, pharmacotherapy,
psychotherapy, and treatment outcomes. Databases’ own controlled vocabulary were used, when
available, in performing the most inclusive search; preventing the chance of missing pertinent
evidence. Resulting in 27 relevant pieces of evidence for critical appraisal. After critically
appraising each study using CATmaker, the results were narrowed down to 14 of the most
reliable and valid pieces of evidence used for synthesis including: 1 systematic review, level A;
and 13, level B, randomized control trials. Modafinil, methadone, buprenorphine, Nacetylcysteine (NAC), mirtazapine, dexamphetamine, and bupropion were associated with
positive treatment outcomes for methamphetamine dependence. However, these studies were
conducted in short time frames with small sample sizes. The research supports further
investigation into these medications as the preliminary studies showed promising results. An
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integrated treatment approach of psychotherapy in combination with pharmacotherapy,
had the most significant results in adults with methamphetamine dependence (Shearer et
al., 2009; Colfax et al., 2011). No evidence was identified for pharmacotherapy treatment
of co-occurring stimulant use disorder methamphetamine-type and PTSD. Conducive to
finding an effective treatment for this comorbidity, further research is required.
Keywords: stimulant use disorder methamphetamine-type, PTSD, cooccurring
disorder, pharmacotherapy, psychotherapy, and treatment outcomes
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Background
Exposure to traumatic events is common, ranging from 55% to 90% of adults in the
United States, will experience at least one traumatic event in their lifetime (Halter, 2014;
National Institute of Mental Health, 2017). However, among individuals with exposure to one or
more traumatic events, only 8% develop PTSD (Halter, 2014; Center for Behavioral Health
Statistics and Quality, 2016). Research has shown, exposure to traumatic events increases the
likelihood of developing a medical illness, mental disorder, substance use disorder, or comorbid
conditions (Halter, 2014; Center for Behavioral Health Statistics and Quality, 2016; Child
Welfare Information Gateway, 2013; National Institute of Mental Health, 2017).
While medications have been approved for the treatment of alcohol use disorder, opioid
use disorder, and PTSD symptoms; the FDA has not approved any medications for the treatment
of methamphetamine use disorder (Perese, 2012; Stahl, 2013). In 2016, an estimated 1,391,000
or 0.5% of persons aged 12 and older in the United States, reported methamphetamine use in the
past year (CDC, 2018). More than 10,721 Americans died from an overdose involving
methamphetamine in 2017 (CDC, 2018). The rate of overdose deaths involving
methamphetamine increased by 33.3% from 2015, with the highest rates found primarily in
smaller towns and in midwestern and western states (CDC, 2018).
The Substance Abuse and Mental Health Services Administration’s 2015 National
Survey on Drug Use and Health reported, approximately 8.1 million adults (3.3 percent of all
adults) in the United States had cooccurring mental health and substance use disorders in 2015
(Center for Behavioral Health Statistics and Quality, 2016). The increasing number of illicit drug
overdoses, deaths, and poorer treatment outcomes associated with this comorbidity elicits a
review of literature relevant to the treatment outcomes of pharmacologic interventions alone or
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in combination with psychotherapy of individuals with co-occurring PTSD and stimulant
use disorder: methamphetamine-type.
La Crosse County Health and Human Services’ Outpatient Mental Health and
Substance Use Clinic serves an increasing population of individuals diagnosed with
cooccurring mental health and substance use disorders in Wisconsin (Integrated Support
& Recovery Services, 2018). During clinical practicum with La Crosse County this fall, a
common theme emerged among patients diagnosed with substance use disorders (SUDs).
Several of the patients had been exposed to at least one traumatic event in their lifetime.
Below, used as an example of the patient population that could benefit from this review,
is a case report of a patient seeking treatment for opioid use, methamphetamine use, and
PTSD symptoms.
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Chief Complaint: “I’m a heroin and meth addict. I need help with my cravings.”
A 31-year-old female client presented for a psychiatric intake appointment seeking
treatment for her addiction to methamphetamine and heroin. Information was obtained from
patient and past medical records. Today, patient reported 30 days of sobriety. Patient was
serving an alternative to revocation from probation sentence, tracked by GPS and tested for drug
and alcohol use. Patient reported her mood, thinking, and ability to concentrate had improved
since being sober. Patient reported feeling hopeful for her future and recovery. Patient’s energy
level was appropriate, not feeling fatigued or hyper throughout the day. Patient was motivated
for treatment.
Patient reported difficulty falling asleep and staying asleep, “I can’t shut my mind
off, it just keeps running.” Patient endorsed restlessness in the evenings, “I have restlessness in
my hands and legs at night.” Patient reported she used Gabapentin in the past to help with
restlessness, sleep, methamphetamine and heroin cravings. Patient denied excessive anxiety or
worry, “I’m nervous about the future but I would say it’s a normal level of anxiety.” Patient’s
anxiety did not interfere with her ability to function. Patient denied mania and psychotic
symptoms.
Patient had a history of sexual abuse, a miscarriage and witnessing a suicide. Patient
reported she had frequent flash backs, relived the traumatic moments, had nightmares once every
few weeks, and was afraid to go to sleep. Patient reported some hypervigilance, but believed it
was related to her substance use.
Patient’s strengths included a good family support system, motivated and determined in
her recovery. Patient reported she was working on trying to think more positively. Patient
enjoyed creating art.
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Patients goals were to: maintain sobriety, change mind set to think more
positively, express herself with art, and learn more coping skills to manage
PTSD symptoms and drug cravings.
Previous psychotropic medication trials included: Gabapentin, Prozac and
Vivitrol injection. Patient had no previous inpatient psychiatric hospitalizations. Patient
denied history of suicide attempts.
Patient had attended an intensive outpatient treatment program for heroin and
methamphetamine use, in the past. Patient was currently receiving therapy services at a
local program designed to help individuals with mental health issues and substance
abuse.
Patient’s past medical history included diagnoses of Opioid Use Disorder and
Hepatitis C. Patient was having regular menstrual periods, was not taking birth control,
but was not currently sexually active. Patient had been pregnant once, but miscarried at 6
weeks gestation. Last physical and set of labs had not been completed for a few years.
Patient was going to see her primary care physician that day. Patient had no known drug
allergies.
Patient was born in the Midwest, where she was raised, and had one brother.
Patient’s parents divorced when she was a teenager. Both parents were in serious
relationships with someone new. Patient was an average student and graduated high
school. Patient was married at age 19 and recently divorced her husband. They used to
use methamphetamine and heroin together. Patient’s brother-in-law
committed suicide. Patient’s father had alcoholism. Her brother was addicted to “K2” and
had ADHD. Patient was unemployed but had been employed at various places
previously.
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Patient was alert, fully attentive, casually dressed and groomed. Appeared average
weight and stated age. Attitude was cooperative and not guarded. Activity was calm, not restless,
no abnormal movements, good eye contact. Patient was fully oriented, memory intact. Mood was
“good, better.” Affect was within normal range, not restricted, flat or labile. Normal expressive
and receptive language function. Thought process was organized, goal directed, and did not
require redirections. Thought content was free from delusions, suicidal and homicidal ideation.
Patient was not attending to internal stimuli. Patient had good insight and judgment appeared to
be improving with sobriety. Patient had a normal gait and station; no tics or tremors were
observed.
Records and labs will be reviewed from primary care visit. A follow-up appointment was
made for 6 weeks out. Preliminary psychiatric diagnoses given include: opioid use disorder,
stimulant use disorder: methamphetamine-type, PTSD rule out acute stress disorder.
Psychotropic medications prescribed were Vivitrol 380 mg intramuscular every 28 days and
gabapentin 300 mg by mouth three times a day as needed for restlessness.
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A Literature Review of Pharmacotherapy Treatment Outcomes for Comorbid Post-Traumatic
Stress Disorder and Methamphetamine Use
What is the evidence that pharmacotherapy alone or in combination with
psychotherapy, improves treatment outcomes in adults diagnosed with cooccurring
stimulant use disorder methamphetamine-type and post-traumatic stress disorder?
Method
The strongest level of evidence, Level A, consists of a meta-analysis of multiple
controlled studies or a meta-synthesis of qualitative studies with results that consistently
support a specific action, intervention or treatment (Armola et al., 2009). The primary
focus of the research would revolve around finding level A studies. However, if level A
evidence was not available, the next level of evidence down the ANCC’s hierarchy of
evidence, level B, would be used. Level B evidence consists of well-designed controlled
studies, both randomized and nonrandomized, with results that consistently support a
specific action, intervention, or treatment (Armola et al., 2009). Continuation down the
hierarchy would be utilized as needed.
Conducive to identifying all relevant studies, multiple bibliographic databases
were used to complete a comprehensive search of evidence. The databases used include:
MEDLINE, Pubmed, CINAHL, and PsycINFO. MEDLINE is the largest health database,
covering over 5,000 journals and other publication types in all areas of health sciences;
therefore, increasing the likelihood of identifying significant evidence (Foreman &
Mateo, 2014). Cumulative Index to Nursing and Allied Health Literature, CINAHL,
provides coverage of 5,000 journals as well as 80 other document types (Foreman &
Mateo, 2014). PsycINFO, a large behavioral science and mental health database
produced by the American Psychological Association and containing more than 3 million
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records from 2,500 journals, books, book chapters and dissertation (Foreman & Mateo, 2014). In
order to warrant the most thorough and relevant results, it was essential for the databases used in
the literature review to cover both healthcare and mental health studies.
Searched keyword phrases included: stimulant use disorder methamphetamine-type,
PTSD, cooccurring disorder, pharmacotherapy, therapy, and treatment outcomes. Databases’
own controlled vocabulary was used, when available, in performing the most inclusive search;
preventing the chance of missing pertinent evidence.
MEDLINE and Pubmed databases were searched using Medical Subject Headings or
MeSH terms from the National Library of Medicine’s controlled vocabulary for MEDLINE
(Fink, 2014; Foreman & Mateo, 2014). Using MeSH, the keyword phrase, stimulant use disorder
methamphetamine-type, was searched, producing no results. No results were found using
Pubmed. Next, keyword phrase methamphetamine use disorder, was searched using MeSH,
which produced the MeSH match term of “methamphetamine.” A Pubmed database search of
methamphetamine produced an overwhelming 8,942 articles. However, a Pubmed database
search of MeSH terms methamphetamine and pharmacology with Boolean connector “AND,”
narrowed results down to 6,180 articles. Continuing with the same search method of one
keyword phrase at a time, using the database-controlled vocabulary, MeSH, then combining the
searches using the Boolean “AND.” A Pubmed database search of MeSH terms,
“methamphetamine” “pharmacology” “treatment outcomes” “mental disorders” connected with
Boolean connector “AND” with limitations of English, humans, and published within the past 10
years; produced 46 articles. Additional combinations of the keyword phrases, “therapy” “posttraumatic stress disorder” produced no results.
Next, it was necessary to determine if any of the 46 articles discovered were metaanalysis, the highest level of evidence. Once the meta-analysis filter was applied to the results,
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one article remained. In order to obtain more results, another filter of randomized
controlled trials was applied and a total of 21 articles remained.
Cumulative Index to Nursing and Allied Health Literature, CINAHL, database
uses a different controlled vocabulary, called CINAHL Subject Headings (Fink, 2014;
Foreman & Mateo, 2014) Keyword phrases and matching terms from CINAHL Subject
Headings were searched in a variety of combinations. Unfortunately, many of the
searches produced zero results. However, the combination of “treatment outcome”
“methamphetamine” and “pharmacological treatment” using the Boolean connector
“AND” produced 4 articles with the limitations of full text, academic journals and peer
reviewed. 3 of the 4 articles were applicable to answering the research question.
Next, using PsycINFO’s thesaurus, each keyword phrase and matching key terms
from the thesaurus were searched independently. Different combinations of keyword
phrases were used in order to thoroughly search for most significant results. Ultimately,
the combination of “methamphetamine” AND “dual diagnosis” AND “treatment
outcomes” AND “pharmacological” yielded the most results. After applying filter
limitations of peer reviewed, full text, academic journal and published within the last 8
years; 2 articles remained and were kept for analysis.
Total, 26 pieces of evidence were identified using Pubmed, MEDLINE, CINAHL,
and PsycINFO’s databases. As a final step in the identification process, using the
ancestry method, a hand search of the reference lists of each remaining study was
conducted; in search of relevant studies that might not have been found in the original
search (Fink, 2014; Foreman & Mateo, 2014). One additional article was discovered,
resulting in 27 relevant pieces of evidence used for critical appraisal. No duplicate
articles were identified.
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CATmaker, an online appraisal tool available through Centers for Evidence-Based
Medicine, was used to critically appraise each article. After performing a rapid critical appraisal
of each article, a total of 13 reliable and valid studies had met inclusion criteria. Consisting of
one level A piece of evidence, a systematic review; and 13, level B pieces of evidence which
were randomized control trials. All 14 pieces of evidence were used in this synthesis of
literature.
Results
In a randomized, double-blind, placebo-controlled trial, Shearer et al., found modafinil
200/mg a day, associated with a reduction in methamphetamine use among methamphetamine
dependent patients (2009). Those who participated in psychotherapy showed better outcomes, as
well as, those who did not have comorbidities (Shearer et al., 2009).
Methadone and buprenorphine have been approved by the FDA for treatment of opioid
use disorder (Stahl, 2017). In a randomized control study, the efficacy of methadone and
buprenorphine in the treatment of methamphetamine withdrawal cravings were examined. Both
medications were effective in reducing methamphetamine use cravings (Ahmadi & Jahromi,
2017). However, those treated with buprenorphine showed significantly more reduction in
cravings compared to those treated with methadone (Ahmadi & Jahromi, 2017). Salehi,
Emadossadat, Kheirabadi, Maracy, and Sharbafchi also found buprenorphine to be effective in
significantly reducing methamphetamine use cravings among individuals addicted to
methamphetamine in a randomized, double-blind, placebo-controlled trial (2015).
A randomized, double-blind, placebo-controlled clinical trial of the amino acid, Nacetylcysteine (NAC), showed good efficacy in suppressing methamphetamine use cravings, in
methamphetamine use dependence (Seyed, Ghafur, Mousavi et al., 2015). A randomized
controlled study showed the addition of mirtazapine to psychotherapy, decreased
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methamphetamine uses among active methamphetamine users (Colfax et al., 2011). A
reanalysis of a multisite, double-blind, placebo-controlled trial showed bupropion to be
effective in facilitating the achievement of abstinence of methamphetamine use amongst
methamphetamine dependent individuals (McCann & Li, 2012).
The pharmacotherapy treatment effects of once-daily dosing of dexamphetamine
sustained release in individuals with methamphetamine use disorder were analyzed in a
randomized controlled trial (Longo et al., 2010). The results were measured by self-report
and hair analysis. Those treated with dexamphetamine, self-reported decrease in
methamphetamine use; hair analysis was used to confirm this finding (Longo et al.,
2010). The use of daily dexamphetamine showed increased treatment retention, decreased
methamphetamine use, decreased dependence and decreased withdrawal symptom
(Longo et al., 2010). However, there was not a significant difference between the placebo
group and the dexamphetamine treated group (Longo et al., 2010). The study supports
further research on pharmacotherapy as a treatment intervention for methamphetamine
dependence. (Longo et al., 2010).
A systematic review and meta-analysis of randomized, placebo-controlled trials
by Kishi, Matsuda, Iwata, and Correll showed no advantages of antipsychotics over the
placebo in psychostimulant abstinence or cravings (2013). Antidepressants were found to
be ineffective in the treatment of methamphetamine use disorder in a randomized
controlled trial by Hellem, Lundberg, and Renshaw (2015). Briones et al., hypothesized
in a randomized double-blind phase II clinical trial, that varenicline, a nicotine receptor
partial agonist, would be effective treatment for methamphetamine dependence due to the
dopaminergic effects (2018). However, the study showed varenicline to be ineffective in
treating methamphetamine use (Briones et al., 2018).
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A multisite randomized clinical trial showed improved patient outcomes using 12-step
sponsors among individuals receiving treatment for stimulant use disorder. (Wendt, Hallgren,
Daley, & Donovan, 2017). Neurofeedback plus pharmacotherapy was shown to be more
effective then pharmacotherapy alone in the of treatment of crystal methamphetamine dependent
patients (Rostami & Dehghani-Arani, 2015). Longer durations of contingency management in
conjunction with psychosocial treatment was found to be effective in abstaining from
methamphetamine use among methamphetamine dependent individuals in a randomized control
trial by Roll, Chudzynski, Cameron, Howell, and McPherson (2013).
Discussion
Modafinil, methadone, buprenorphine, N-acetylcysteine (NAC), mirtazapine,
dexamphetamine, and bupropion were associated with positive treatment outcomes amongst
individuals with methamphetamine dependence as evidence by decreased cravings to use meth
and longer periods of abstaining from methamphetamine use (Ahmadi & Jahromi, 2017; Salehi
et al., 2015; Shearer et al., 2009; Seyed, Ghafur, & Mousavi et al., 2015; Colfax et al., 201;
McCann & Li, 2012; Longo et al., 2010). An integrated treatment approach of psychotherapy in
combination with pharmacotherapy, had the most significant results in adults with
methamphetamine dependence (Shearer et al., 2009; Colfax et al., 2011). Neurofeedback,
sponsorship, and longer durations of contingency management in conjunction with
pharmacotherapy, showed improved treatment outcomes amongst adults seeking treatment for
stimulant use disorder (Wendt et al., 2017; Rostami & Dehghani-Arani, 2015; Roll, Chudzynski,
Cameron, Howell, & McPherson, 2013). Antipsychotics, antidepressants and varenicline,
showed to be ineffective in treatment of methamphetamine use (Kishi et al., 2013; Hellem,
Lundberg, & Renshaw, 2015; Briones et al., 2018).
Limitations of These Studies

PHARMACOTHERAPY FOR PTSD AND METHAMPHETAMINE USE

16

Several of the randomized controlled trials studying the efficacy of pharmacotherapy in
individuals with methamphetamine use disorder, analyzed in this literature review; were faced
with many barriers and limitations. Sample sizes were too small, many participants dropped out
of the studies related to their substance use, difficulty of monitoring medication compliance
amongst the control groups and mediating factors such as severity or duration of use that could
may influence results, were not controlled. Scarce literature on treatment of comorbidities was
identified. Multiple searches yielded no results with the addition of keyword phrases of
comorbidity, trauma, and post-traumatic stress disorders; showing a lacking amount of evidence
pertaining to the treatment of cooccurring stimulant use disorder: methamphetamine-type and
post-traumatic stress disorder.
Conclusions and Future Study
An insufficient amount of literature is available on the treatment of cooccurring
stimulant use disorder: methamphetamine-type and post-traumatic stress disorder
supports my recommendation for further research on the treatment of this comorbidity.
Despite years of effort and several randomized controlled trials, an effective medication
for the treatment of methamphetamine dependence, has yet to emerge. While modafinil,
methadone, buprenorphine, N-acetylcysteine (NAC), mirtazapine, dexamphetamine, and
bupropion have been associated with positive treatment outcomes amongst individuals
with methamphetamine dependence as evidence by decreased cravings to use
methamphetamine and longer periods of abstaining from methamphetamine use; these
studies were conducted in short time frames with small sample sizes. The research
supports further investigation into these medications as preliminary studies show
promising results.
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